Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 5/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010133 | 1.00 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL16925663 | 0.94 | KMT2A (0.53) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL29531876 | 0.91 | TLR2 (0.54) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL31493934 | 0.89 | TLR2 (0.51) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL29521704 | 0.89 | TLR2 (0.51) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL5312217 | 0.89 | TLR2 (0.51) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL29400519 | 0.89 | TLR2 (0.51) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL12852253 | 0.89 | TLR2 (0.51) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL14770862 | 0.88 | TLR2 (0.44) | KMT2ATLR2MDM2 | |
| SCHEMBL30546904 | 0.86 | TLR2 (0.48) | KMT2ATLR2TLR1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | PFIZER, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018138591-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | KMT2A 3582/4885TLR2 1653/4885TLR1 2103/4885 |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | STT3A, CLSPN, STT3B | KMT2A 3063/4885TLR2 1822/4885TLR1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.